Podcasts about biomedical technology

Professor Stephen Quake's research has helped countless patients avoid the pain and suffering that can come with invasive diagnostic testing. Russ and Stephen discuss his work to develop a number of noninvasive blood tests to help detect preterm births, genetic disorders like Down Syndrome, cancer, and organ transplant rejection. It's an episode that reminds us of the power of good science. We hope you'll take another listen and enjoy.Links:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads or Twitter/XConnect with School of Engineering >>> Twitter/XChapters:(00:00:00) IntroductionHost Russ Altman introduces the episode featuring Dr. Stephen Quake, highlighting his contributions to non-invasive blood tests. (00:00:46) Understanding DNA in DiagnosticsIntroduction to the revelation of detecting DNA in the bloodstream, shedding light on various bodily processes.(00:02:24) The Beginning of Dr. Quake's work with Cell Free DNADr. Quake tells the story of his journey into research with cell free DNA beginning with searching for a less risky alternative to an amniocentesis(00:05:11) Impact on Prenatal TestingThe transformation in prenatal diagnostics, replacing invasive tests  & understanding the detection capabilities for prenatal genetic disorders like using cell-free DNA.(00:06:39) Transplant Rejection MonitoringThe discovery of cell free DNA & it's use in heart & lung transplant patients detecting early rejection & the real-life implications of this technology.(00:10:35) Unveiling Infectious AgentsThe detection of infectious agents in blood & the real life applications of this discovery(00:14:52) Advances in Cancer DetectionDiscussion shifts to cancer detection using cell-free DNA, emphasizing the important application of monitoring cancer progression and treatment efficacy. (00:17:18) Predicting Preterm BirthDr. Quake delves into the groundbreaking research predicting preterm births using cell-free RNA and DNA, sharing insights into discoveries indicating preterm birth risks and gestational age predictions and the significance of this.(00:21:42) The Chan Zuckerberg Biohub's MissionThe origins and bold mission of Steve Quake's current work at the Chan Zuckerberg Biohub, to cure, treat, or prevent all human diseases by the end of the century and the feasibility of such an ambitious goal. (00:24:03) Biohub's Research StrategyBiohub's strategy focusing on cell biology and infectious diseases internally, while funding nearly a hundred faculty across diverse areas in Bay Area Universities.(00:26:26) Conclusion  LINKS:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads or Twitter/XConnect with School of Engineering >>> Twitter/X

This episode features Dr. Howard Rosing, CEO of Global Biomedical Technology. Here, he discusses his background & what led him to found Global Biomedical Technology, his transition out of practicing medicine, and Comfort Release - an adhesive bandage designed for pain-free removal.

(0:42) - A Spy In The Belly--As always, you can find these and other interesting & impactful engineering articles on Wevolver.com.To learn more about this show, please visit our shows page. By following the page, you will get automatic updates by email when a new show is published. Be sure to give us a follow and review on Apple podcasts, Spotify, and most of your favorite podcast platforms!

The second segment of the stroke series explore biomedical technology and it's role in enhancing stroke treatments. We take a look at how artificial intelligence is being used expedite acute stroke care, minimize residual brain damage, and ultimately improve patient outcomes. Additionally, we discuss neuroplasticity and the implications of early and aggressive rehabilitation protocols. Emerging research including virtual reality, natural stem cell therapy, and vagus nerve stimulation are also visited within this episode.

Ondine Biomedical CEO Carolyn Cross joined Steve Darling from Proactive to share news about the company that is on a mission to improve outcomes in hospitals when it comes to dealing with infections. Cross talks about their patented, painless, photodisinfection technology platform for the prevention of broad-spectrum pathogens which are bacterial, viral and fungal. That process involves a two-step process with the application of a laser light-activated agent to each nostril, followed by illumination of the area via laser light for less than five minutes.

They say, “good talent is hard to find!” This is especially true for emerging high-growth markets where many in the workforce lack the advanced skills necessary to aid their bioproduction needs and expand their market profile. Leveraging the success of the M Lab™ Collaboration Centers, the MilliporeSigma team was able to foster key collaborations with government agencies to provide essential hands-on training programs in various Asia-Pacific countries such as Singapore and Taiwan. In this podcast, we will hear from the individuals that were integral to launching these vital initiatives. Chii-Wann Lin, PhD Vice President and General Director of Biomedical Technology and Device Research Laboratories, and Industrial Technology Research Institute (ITRI). Chin Bin Tan, Head of Technology Management, APAC, MilliporeSigma. This is part two in the five-part podcast series tackling diverse issues such as the need for speed to market in gene therapy, next-generation bioprocessing, and viral safety assurance in upstream and downstream. Make sure you check back regularly to hear the latest GENcast session.

Thibaut Balabonski (LRI, France and University of Paris-Sud, France) gives the third talk in the second panel, Foundations of Higher-Order Programming, on the 2nd day of the ICFP conference. Co-written by Pablo Barenbaum (University of Buenos Aires, Argentina/IRIF, France/University of Paris Diderot, France), Eduardo Bonelli (CONICET, Argentina/Universidad Nacional de Quilmes, Argentina), Delia Kesner (IRIF/University of Paris Diderot, France). We present a call-by-need strategy for computing strong normal forms of open terms (reduction is admitted inside the body of abstractions and substitutions, and the terms may contain free variables), which guarantees that arguments are only evaluated when needed and at most once. The strategy is shown to be complete with respect to beta-reduction to strong normal form. The proof of completeness relies on two key tools: (1) the definition of a strong call-by-need calculus where reduction may be performed inside any context, and (2) the use of non-idempotent intersection types. More precisely, terms admitting a beta-normal form in pure lambda calculus are typable, typability implies (weak) normalisation in the strong call-by-need calculus, and weak normalisation in the strong call-by-need calculus implies normalisation in the strong call-by-need strategy. Our (strong) call-by-need strategy is also shown to be conservative over the standard (weak) call-by-need.

In this double seminar, Erasmus visitors Laurentiu Staicu and Emanuel-Mihail Socaciua discuss the rise of biomedical technology and some of the legal issues of moral bioenhancement 'The rise of postmedicine: some ethical concerns regarding biomedical technology'. Traditional medicine is bound by a moral duty to treat patients with compassion and to combine all medical interventions and treatments with caring as a fundamental attitude toward the patient. That's because the patient is seen as a person who needs help in recovering his or hers well-being, and any person should be treated with care and respect. However, what happens when patients are seen as medical puzzles which need to be solved rather than people in need? Can we treat a puzzle with care and compassion? The use of biomedical technology in medical treatments brought a spectacular increase in efficiency, but what are the moral costs of this increased efficiency? (Speaker: Laurentiu Staicu) 'How Drug Patents Might Lead to Disincentives for Moral Bioenhancement'. Biological moral enhancement (BME) and intellectual property (IP) might seem two entirely distinct areas. While BME refers to moral enhancement techniques which presuppose the use of biological means, the moral and legal debate surrounding IP tries to tackle the issue of whether ideas could/should be appropriated. In our paper we wish to link the two debates by exploring the consequences of the current IP and patent system in relation to the propensity of individuals to become morally enhanced through drugs or other pharmaceutical compounds. If artificial scarcity is one of the intended consequences of patents, we argue in favor of the following (weak) thesis: intellectual property rights provide noticeable disincentives for individual and voluntary moral bioenhancement.(Speaker: Emanuel-Mihail Socaciua)

In this double seminar, Erasmus visitors Laurentiu Staicu and Emanuel-Mihail Socaciua discuss the rise of biomedical technology and some of the legal issues of moral bioenhancement 'The rise of postmedicine: some ethical concerns regarding biomedical technology'. Traditional medicine is bound by a moral duty to treat patients with compassion and to combine all medical interventions and treatments with caring as a fundamental attitude toward the patient. That's because the patient is seen as a person who needs help in recovering his or hers well-being, and any person should be treated with care and respect. However, what happens when patients are seen as medical puzzles which need to be solved rather than people in need? Can we treat a puzzle with care and compassion? The use of biomedical technology in medical treatments brought a spectacular increase in efficiency, but what are the moral costs of this increased efficiency? (Speaker: Laurentiu Staicu) 'How Drug Patents Might Lead to Disincentives for Moral Bioenhancement'. Biological moral enhancement (BME) and intellectual property (IP) might seem two entirely distinct areas. While BME refers to moral enhancement techniques which presuppose the use of biological means, the moral and legal debate surrounding IP tries to tackle the issue of whether ideas could/should be appropriated. In our paper we wish to link the two debates by exploring the consequences of the current IP and patent system in relation to the propensity of individuals to become morally enhanced through drugs or other pharmaceutical compounds. If artificial scarcity is one of the intended consequences of patents, we argue in favor of the following (weak) thesis: intellectual property rights provide noticeable disincentives for individual and voluntary moral bioenhancement.(Speaker: Emanuel-Mihail Socaciua)

American Psychiatric Association President Dr. Jeffrey Lieberman on how government policies are out of sync with our country's medical needs.

How far should athletes go in pursuit of the podium? Ethics Bites asked Michael Sandel about sport and genetic enhancement. Find out more about Michael, and ethics, at www.open2.net/ethicsbites.

Transcript -- How far should athletes go in pursuit of the podium? Ethics Bites asked Michael Sandel about sport and genetic enhancement. Find out more about Michael, and ethics, at www.open2.net/ethicsbites.